[Cutaneous side effects of the multikinase inhibitors sorafenib and sunitinib]. / Kutane Nebenwirkungen der Multikinaseinhibitoren Sorafenib und Sunitinib.
Hautarzt
; 61(8): 662-7, 2010 Aug.
Article
en De
| MEDLINE
| ID: mdl-20631979
Molecular targeted therapy with monoclonal antibodies and low molecular weight inhibitors is gaining increasing importance particularly in the treatment of malignant tumors. These drugs are specific and highly selective agents that intervene in the dysfunctional regulatory processes of malignant cells in order to influence cell proliferation, cell differentiation, or angiogenesis. The multikinase inhibitors sorafenib and sunitinib exhibit a favorable tolerability profile and spectrum of side effects, especially in comparison to conventional chemotherapeutic agents. However, they induce specific cutaneous side effects that can in turn be indicators of antitumor activity. This review article compares the cutaneous side effects of the two multikinase inhibitors sorafenib and sunitinib and discusses the therapeutic options for the individual cutaneous reaction patterns.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Piridinas
/
Bencenosulfonatos
/
Erupciones por Medicamentos
/
Inhibidores de Proteínas Quinasas
/
Antineoplásicos
Tipo de estudio:
Diagnostic_studies
Límite:
Humans
Idioma:
De
Revista:
Hautarzt
Año:
2010
Tipo del documento:
Article
Pais de publicación:
Alemania